Sedation With Remimazolam During Spinal Anesthesia
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Remimazolam is a benzodiazepine-binding site antagonist of the GABA receptor, metabolized by
esterases, and exhibits a stable context-sensitive half-life of 6-7 minutes. Remimazolam has
a high clearance rate and a small volume of distribution in the pharmacokinetic model. The US
FDA has approved sedation for surgery. Although there have been studies on the use of
remimazolam as a sedative for procedures such as endoscopy, there have been no reports of the
use of remimazolam in spinal anesthesia. The purpose of this study is to compare and analyze
the hemodynamics and recovery profile of patients undergoing surgery under spinal anesthesia
by maintaining sedation with dexmedetomidine or remimazolam.